---
document_datetime: 2023-09-21 19:04:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/cystadane-epar-procedural-steps-taken-authorisation_en.pdf
document_name: cystadane-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4188977
conversion_datetime: 2025-12-20 12:26:39.645588
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## Submission of the dossier

The  applicant  Orphan  Europe  S.A.R.L.  submitted  on  12  July  2005  an  application  for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  through  the  centralised  procedure  for Cystadane,  which  was  designated  as  an  orphan  medicinal  product  EU/3/01/45  on  9  July  2001. Cystadane was designated as an orphan medicinal product in the following indication:  treatment of homocystinuria. The calculated prevalence of this condition was 1.65 per 100,000 EU population

The applicant applied for the following indication treatment of homocystinuria.

The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application

## The application submitted is a complete dossier:

composed of administrative information, complete quality data, non-clinical and clinical data based on applicants'  own  tests  and  studies  and  bibliographic  literature  substituting/supporting  certain  tests  or studies.

## Scientific Advice:

The applicant did not seek scientific advice at the CHMP.

## Licensing status:

Cystadane has been given a Marketing Authorisation in Australia on 01/10/1996, in USA on 25/10/1996, in Canada on 03/07/1998 and in Israel on 13/09/1998.

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur:

Dr Harald Enzmann

Co-Rapporteur:

Dr Ian Hudson

## Steps taken for the assessment of the product

- The application was received by the EMEA on 12 July 2005.
- The procedure started on 17 August 2005.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 27 October 2005. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 27 October 2005.
- During  the  meeting  on  14  December  2005,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 15 December 2005.
- The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  31 August 2006 after extending the deadline for submitting their responses (extension agreed at the CHMP level).
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 20 October 2006.
- During the CHMP meeting on 16 November 2006, the CHMP agreed on a List of outstanding issues to be addressed in writing by the applicant.
- The applicant provided responses to the List of outstanding issues on 23 November 2006.
- During the meeting on 14 December 2006, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Cystadane. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 14 December 2006.